Enterprise record

Monte Rosa Therapeutics, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:4c73d323-73f1-488a-bdd2-da194d006937Version: public-1As of: unavailable

28 published Claims4 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 3 claims
    • Legal Name: Monte Rosa Therapeutics, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026

  2. SEC DEF 14A 0001193125-26-191439

    sec def 14a · Source published: Apr 29, 2026 · Retrieved: Sep 6, 2026

    Supports 10 claims
    • Leadership Role: Andrew Schiff: Non-Executive Chair of the Board · Claim reviewed: Sep 28, 2026
    • Leadership Role: Anthony Manning: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Eric Hughes: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jan Skvarka: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Markus Warmuth: Chief Executive Officer, President and Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Filip Janku: Chief Medical Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jennifer Champoux: Chief Operating Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Markus Warmuth: Chief Executive Officer and President · Claim reviewed: Sep 28, 2026
    • Leadership Role: Philip Nickson: Chief Business and Legal Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Sharon Townson: Chief Scientific Officer · Claim reviewed: Sep 28, 2026

  3. DEF 14A glue-20260429.htm

    sec proxy · Source published: Apr 29, 2026 · Retrieved: Sep 2, 2026

    Supports 7 claims
    • Leadership Role: Ali Behbahani: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Anthony Manning, Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Chandra P. Leo: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Christine Siu: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Eric Hughes, M.D., Ph.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Kimberly L. Blackwell: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Markus Warmuth, M.D.: Director · Claim reviewed: Sep 28, 2026

  4. GLUE DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 15, 2026

    Supports 8 claims
    • Leadership Role: Anthony Manning, Ph.D.: Named Executive Officer / Director Nominee · Claim reviewed: Sep 28, 2026
    • Leadership Role: Champoux: Chief Operating Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Eric Hughes, M.D., Ph.D.: Named Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Filip Janku, M.D., Ph.D.: Named Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jan Skvarka, Ph.D., MBA: Named Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Markus Warmuth, M.D.: Chief Executive Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Philip Nickson, J.D., Ph.D.: Chief Business and Legal Officer · Claim reviewed: Sep 28, 2026
    • Leadership Role: Townson: Chief Scientific Officer · Claim reviewed: Sep 28, 2026